What does PHARMACIE DU ROOSENDAEL do?

PHARMACIE DU ROOSENDAEL is a pharmacy in Ukkel. Private Limited, started on 5 February 2019, 1 establishment.

What is the address of PHARMACIE DU ROOSENDAEL?

The registered office of PHARMACIE DU ROOSENDAEL is located at Alsembergsesteenweg 432, 1180 Ukkel.

Is PHARMACIE DU ROOSENDAEL still active?

Yes. According to the CBE (31 October 2026) PHARMACIE DU ROOSENDAEL is active, legal situation “Normale toestand”, started on 5 February 2019.

Is PHARMACIE DU ROOSENDAEL registered on Peppol?

Yes, PHARMACIE DU ROOSENDAEL is registered on the Peppol network with ID 0208:0719831159.

What is the enterprise number of PHARMACIE DU ROOSENDAEL?

The enterprise number of PHARMACIE DU ROOSENDAEL is BE0719831159.

When was PHARMACIE DU ROOSENDAEL founded?

PHARMACIE DU ROOSENDAEL was founded on 5 February 2019.

Who are the directors of PHARMACIE DU ROOSENDAEL?

According to the 2025 annual accounts, the directors of PHARMACIE DU ROOSENDAEL are: AGANJU HOLDING SRL.

Is PHARMACIE DU ROOSENDAEL a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 5 February 2019; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did PHARMACIE DU ROOSENDAEL make in 2025?

PHARMACIE DU ROOSENDAEL posted a profit after taxes of € 29,619 in financial year 2025.

What is the revenue of PHARMACIE DU ROOSENDAEL?

As a small company, PHARMACIE DU ROOSENDAEL is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 215,355.

How much does an employee at PHARMACIE DU ROOSENDAEL earn?

The average wage cost per full-time employee at PHARMACIE DU ROOSENDAEL was € 47,000 in 2024: staff costs of € 93,946 for 2 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does PHARMACIE DU ROOSENDAEL have?

According to the 2025 annual accounts, PHARMACIE DU ROOSENDAEL has 0 full-time equivalents (FTE).

PHARMACIE DU ROOSENDAEL (Private Limited) - Ukkel

Dossier PHARMACIE DU ROOSENDAEL, printed on 1 November 2026 from databakkes.be/en/0719831159/pharmacie-du-roosendael. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

PHARMACIE DU ROOSENDAEL from Ukkel, company number BE0719831159, closed financial year 2025 with a result of € 29,619 after tax. For that financial year PHARMACIE DU ROOSENDAEL recorded a gross margin of € 215,355 and equity of € 60,032. Compared with financial year 2024, the result moved from € 28,990 to € 29,619. Profitable, and profit is growing. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.

What it is worth Healthy

€ 60,032

▼ 15% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 29,619

▲ 2% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 49,982

▲ 207% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 40,000 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents

▼ 2 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 114,647

▲ 22% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 17,655

▼ 26% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 4 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 244,534

▼ 20% vs 2024

€ 64,394 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.

Owed to suppliers

€ 162,591

▲ 44% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 43,278

▲ 20% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 141,720 Gross margin 2022: € 141,720 First fiscal year in the series	€ 148,518 Gross margin 2023: € 148,518 ▲ 5% vs 2022 (€ 141,720) Favourable step	€ 189,934 Gross margin 2024: € 189,934 ▲ 28% vs 2023 (€ 148,518) Favourable step	€ 215,355 Gross margin 2025: € 215,355 ▲ 13% vs 2024 (€ 189,934) Favourable step	▲ 13%
Profit after taxes	€ 12,753 Profit after taxes 2022: € 12,753 First fiscal year in the series	€ 2,914 Profit after taxes 2023: € 2,914 ▼ 77% vs 2022 (€ 12,753) Unfavourable step	€ 28,990 Profit after taxes 2024: € 28,990 ▲ € 26,076 vs 2023 (€ 2,914) Favourable step	€ 29,619 Profit after taxes 2025: € 29,619 ▲ 2% vs 2024 (€ 28,990) Favourable step	▲ 2%
Equity	€ 78,510 Equity 2022: € 78,510 First fiscal year in the series	€ 81,424 Equity 2023: € 81,424 ▲ 4% vs 2022 (€ 78,510) Favourable step	€ 70,414 Equity 2024: € 70,414 ▼ 14% vs 2023 (€ 81,424) Unfavourable step	€ 60,032 Equity 2025: € 60,032 ▼ 15% vs 2024 (€ 70,414) Unfavourable step	▼ 15%
Total debts	€ 457,150 Total debts 2022: € 457,150 First fiscal year in the series	€ 446,190 Total debts 2023: € 446,190 ▼ 2% vs 2022 (€ 457,150) Favourable step	€ 495,263 Total debts 2024: € 495,263 ▲ 11% vs 2023 (€ 446,190) Unfavourable step	€ 490,755 Total debts 2025: € 490,755 ▼ 1% vs 2024 (€ 495,263) Favourable step	▼ 1%
Cash	€ 51,197 Cash 2022: € 51,197 First fiscal year in the series	€ 47,917 Cash 2023: € 47,917 ▼ 6% vs 2022 (€ 51,197) Unfavourable step	€ 16,266 Cash 2024: € 16,266 ▼ 66% vs 2023 (€ 47,917) Unfavourable step	€ 49,982 Cash 2025: € 49,982 ▲ 207% vs 2024 (€ 16,266) Favourable step	▲ 207%
Retained profit	€ 48,510 Retained profit 2022: € 48,510 First fiscal year in the series	€ 51,424 Retained profit 2023: € 51,424 ▲ 6% vs 2022 (€ 48,510) Favourable step	€ 40,414 Retained profit 2024: € 40,414 ▼ 21% vs 2023 (€ 51,424) Unfavourable step	€ 30,032 Retained profit 2025: € 30,032 ▼ 26% vs 2024 (€ 40,414) Unfavourable step	▼ 26%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 40,000 Dividend 2024: € 40,000 Unchanged (€ 0) Unchanged	€ 40,000 Dividend 2025: € 40,000 Unchanged (€ 40,000) Unchanged
Bank debt	€ 304,844 Bank debt 2022: € 304,844 First fiscal year in the series	€ 285,997 Bank debt 2023: € 285,997 ▼ 6% vs 2022 (€ 304,844) Favourable step	€ 306,375 Bank debt 2024: € 306,375 ▲ 7% vs 2023 (€ 285,997) Unfavourable step	€ 244,534 Bank debt 2025: € 244,534 ▼ 20% vs 2024 (€ 306,375) Favourable step	▼ 20%
Balance sheet total	€ 535,660 Balance sheet total 2022: € 535,660 First fiscal year in the series	€ 527,614 Balance sheet total 2023: € 527,614 ▼ 2% vs 2022 (€ 535,660) Unchanged	€ 565,677 Balance sheet total 2024: € 565,677 ▲ 7% vs 2023 (€ 527,614) Unchanged	€ 550,788 Balance sheet total 2025: € 550,788 ▼ 3% vs 2024 (€ 565,677) Unchanged	▼ 3%
Employees (FTE)	1.5 Employees (FTE) 2022: 1.5 First fiscal year in the series	2 Employees (FTE) 2023: 2 ▲ 0.5 vs 2022 (1.5) Unchanged	2 Employees (FTE) 2024: 2 Unchanged (2) Unchanged	0 Employees (FTE) 2025: 0 ▼ 2 vs 2024 (2) Unchanged	▼ 2

Key figures of PHARMACIE DU ROOSENDAEL, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARMACIE DU ROOSENDAEL?

What happened at PHARMACIE DU ROOSENDAEL in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 31, 2026 New annual accounts for financial year 2025: profit of € 29,619 (▲ 2% vs 2024). filed late Source: NBB ↗
Mar 1, 2019 New establishment in Ukkel. KBO
2019 AGANJU HOLDING SRL became a director. NBB
Feb 5, 2019 Start of the company according to the CBE. KBO

In short

From € 12,753 profit in 2022 to € 29,619 profit in 2025.

Paid € 30,873 in corporate taxes since 2022.

Best year ever: 2025, with € 29,619 profit.

On average € 95,000 of value added per employee in 2024.

Original PDFs at the National Bank ↗

Management

AGANJU HOLDING 100%

The stake of AGANJU HOLDING comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

PHARMACIE DU ROOSENDAEL

Behind PHARMACIE DU ROOSENDAEL is AGANJU HOLDING SRL. The shares are held by AGANJU HOLDING (100%).

Directors

According to the 2025 annual accounts

AGANJU HOLDING SRL

Director · represented by HAMIAFO NGATCHI HERVE

Also active at: AGANJU CONCEPT, D5-PHARMA, PHARMACIE DES ARCHIDUCS, D4-PHARMA, CENTRE MEDICAL DEWAND

since 2019

Shareholders

AGANJU HOLDING

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Alsembergsesteenweg 432

1180 Ukkel

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 6 companies are registered at this address.

All companies at this address →

LEASCOM

R.V.D. International

BRUXY

€ 24,345 gross margin · 2025

SIGA PHARM

€ 38,501 gross margin · 2024

ELA SERVICES

€ 47,470 gross margin · 2024

+1 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0719.831.159
VAT number: BE 0719.831.159
Registered office: Alsembergsesteenweg 432, 1180 Ukkel
Names & denominations: PHARMACIE DU ROOSENDAEL
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 5 February 2019
Peppol: Active · Active since 12 Dec 2025
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗